Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Universidad De La República currently has 2 pending office actions in its patent portfolio. These actions are being reviewed by 2 distinct examiners, which suggests that each pending matter is receiving an individual assessment. Interestingly, the data indicates that there are 0 distinct art units associated with these actions, which may point to a specific stage in the administrative processing of these filings.
The busiest examiner for the university is GANGLE, BRIAN J, who is responsible for 1 pending office action. Given that there are 2 pending actions in total, GANGLE, BRIAN J handles exactly half of the current workload. The other half is managed by the second of the 2 distinct examiners. This distribution ensures that the university's prosecution outcomes are not solely dependent on the decisions of one individual.
Practitioners working with Universidad De La República should note the balance between the 2 pending office actions and the 2 distinct examiners. Without a designated technology area or art unit in the current data, the focus remains on the individual interactions with the examining corps. The role of GANGLE, BRIAN J and the other examiner will be critical in determining the path forward for these 2 pending actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18644300 | Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18883051 | VERSATILE IMMUNOGENIC MODULES AND NANOPARTICLES FOR TICK VACCINES | GANGLE, BRIAN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18883051 | VERSATILE IMMUNOGENIC MODULES AND NANOPARTICLES FOR TICK VACCINES | GANGLE, BRIAN J | — |
| 18644300 | Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators | WILLIS, DOUGLAS M | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18883051 | VERSATILE IMMUNOGENIC MODULES AND NANOPARTICLES FOR TICK VACCINES | GANGLE, BRIAN J | — | §102§112 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18644300 | Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators | WILLIS, DOUGLAS M | — | DP | Final Rejection | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial